FDA raises cognitive concerns with PCSK9s; Amgen, Sanofi, Regeneron hit
This article was originally published in Scrip
Executive Summary
Perhaps it was the massive snowstorm that walloped the Northeast on 13 February – one among many striking the US this winter – that had everyone so preoccupied that no one noticed tucked inside Regeneron Pharmaceuticals' annual report was a disclosure the FDA was probing adverse neurocognitive events in PCSK9 inhibitors, a new class of investigational agents aimed at reducing low-density lipoprotein (LDL) cholesterol.
You may also be interested in...
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Clinton's Drug Price Plan: Threat Or Flash In The Political Pan?
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.